SPACR (sialoprotein associated with cones and rods), is the major 147-150-kDa glycoprotein present in the insoluble interphotoreceptor matrix of the human retina. Immunocytochemistry localizes SPACR to the matrix surrounding rods and cones (Acharya, S., Rayborn, M. E., and Hollyfield, J. G. (1998) Glycobiology 8, 997-1006). From affinity-purified SPACR, we obtained seven peptide sequences showing 100% identity to the deduced sequence of IMPG1, a purported chondroitin 6-sulfate proteoglycan core protein, which binds peanut agglutinin and is localized to the interphotoreceptor matrix. We show here that SPACR is the most prominent 147-150-kDa band present in the interphotoreceptor matrix and is the gene product of IMPG1. SPACR is not a chondroitin sulfate proteoglycan, since it is not a product of chondroitinase ABC digestion and does not react to a specific antibody for chondroitin 6-sulfate proteoglycan. Moreover, the deduced amino acid sequence reveals no established glycosaminoglycan attachment site. One hyaluronan binding motif is present in the predicted sequence of SPACR. We present evidence that SPACR has a functional hyaluronan binding domain, suggesting that interactions between SPACR and hyaluronan may serve to form the basic macromolecular scaffold, which comprises the insoluble interphotoreceptor matrix.
The IPM 1 resides within the outer eye wall, at the interface between the neural retina and the retinal pigment epithelium. Projecting from the neural retina outer surface, the elongate photoreceptor inner and outer segments penetrate into and are surrounded by the IPM (1) . A number of activities of fundamental importance to vision are thought to be mediated by the IPM, including retinal adhesion, visual pigment chromophore exchange, metabolite trafficking, photoreceptor alignment, and membrane turnover (2) . The specific IPM molecules that participate in these activities are not well defined.
The distribution of wheat germ agglutinin (WGA)-binding domains in the IPM surrounding rod and cone photoreceptors has previously been documented (3) . These matrix components are relatively stable and resist extraction with physiological salt solutions. A major WGA-binding glycoprotein, glycoprotein 147, was identified in extracts of the insoluble IPM from human retina (4) . More recently, this protein was purified from the insoluble IPM and characterized (5) . The glycoprotein was renamed SPACR, which is an acronym for "sialoprotein associated with cones and rods" (5) . A polyclonal antibody prepared against SPACR intensely labels the rod-associated matrix with weaker labeling of the matrix surrounding cones (5) . This pattern and intensity of immunoreactivity mimics the differential distribution of WGA binding to the rod and cone matrix domains. Using a variety of lectins in conjunction with neuraminidase and glycosidase digestions, we established that (a) the molecule is heavily sialylated, (b) both N-and O-linked glycoconjugates are present in the molecule, and (c) glycoconjugates account for approximately 30% of the molecular mass (5) .
To obtain sufficient amino acid sequence from purified SPACR, which would permit cloning of the gene, SPACR peptides were sequenced and found to be identical to predicted peptides encoded by the cDNA of IMPG1 (also called IPM150, accession number AF047492). The gene product of IMPG1 is reported to be a chondroitin sulfate proteoglycan core protein present in the IPM (6 -10) . Although both IMPG1 and SPACR are located in the IPM, our earlier studies demonstrated that SPACR is a glycoprotein and not a proteoglycan (5) . Could SPACR and IMPG1 be products of the same gene, differing only in post-translational modifications? In this study we present evidence demonstrating that the gene product of IMPG1 is not a proteoglycan, but instead is the IPM glycoprotein SPACR. Furthermore, we demonstrate that one function of SPACR is to bind and organize HA in the IPM.
EXPERIMENTAL PROCEDURES
Reagents-The lectins WGA and peanut agglutinin (PNA), biotinylated horseradish peroxidase, streptavidin, and goat anti-rabbit IgG were obtained from Vector Laboratories (Burlingame, CA). Nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate tablets, iodoacetic acid, and dithiothreitol were purchased from Sigma. Protease inhibitors were from Boehringer Mannheim. Diaminobenzidine tablets were from Amresco (Solon, OH). Biotinylated chondroitin 6-sulfate ⌬-disaccharide-specific antibody (3B3), chondroitinase ABC (protease-free), chondroitinase ACII (protease-free), and Streptomyces hyaluronidase were purchased from Seikagaku Corp. (Ijamsville, MD). Sequencing grade trypsin was from Boehringer Mannheim. Endoproteinase Lys-C and endoproteinase Glu-C were purchased from Waco Bioproducts (Richmond, VA). Cetylpyridinium chloride was obtained from ICN Biomedicals (Aurora, OH). Immobilon P membranes were purchased from Millipore (Bedford, MA). Healon (Amersham Pharmacia Biotech, Uppsala, Sweden) was the source of HA. Gel Code stain was obtained from Pierce.
IPM Isolation-Sixty-five human eyes were obtained from the Cleveland Eye Bank (Cleveland, OH) for use in this study. Donor ages ranged * This work was supported by National Institutes of Health Grant EY 02362 and grants from the Foundation Fighting Blindness (Hunt Valley, MD), the Retina Research Foundation (Houston, TX), and funds from the Cleveland Clinic Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1 The abbreviations used are: IPM, interphotoreceptor matrix; IMPG1, interphotoreceptor matrix proteoglycan 1; BSA, bovine serum albumin; CPC, cetylpyridinium chloride; EGF, epidermal growth factor; GAG, glycosaminoglycan; HA, hyaluronan; PAGE, polyacrylamide gel electrophoresis; PNA, peanut agglutinin; RHAMM, receptor for hyaluronan mediated motility; SPACR, sialoprotein associated with cones and rods; TBS, Tris-buffered saline; 3B3, chondroitin 6-sulfate ⌬-disaccharide-specific antibody; WGA, wheat germ agglutinin; MOPS, 4-morpholinepropanesulfonic acid. from 4 to 70 years, with postmortem times between 2 and 12 h. Retinas were isolated and washed extensively with phosphate-buffered saline containing protease inhibitors to remove soluble components, followed by detachment of the insoluble IPM with distilled water (3, 11, 12) . The insoluble IPM was collected (5) after centrifugation, and the pellet was solubilized in 0.1 M TBS, pH 8.0, containing 5 mM dithiothreitol.
SPACR Purification-This procedure was performed as described earlier (5) . SPACR was solubilized in 0.1 M TBS, pH 8.0, containing 5 mM dithiothreitol. The supernatant was dialyzed against the same buffer before loading on a PNA-agarose column. The flow-through from this column was then applied to a WGA-Sepharose column, and the protein eluted with 0.25 M N-acetyl-D-glucosamine. Individual fractions were analyzed for purity by SDS-PAGE, followed by lectin blotting using biotinylated WGA, and stored as individual fractions at Ϫ70°C.
Chondroitinase ABC/ACII Digestion-50 ml of 1 mg/ml IPM extract was resuspended in 0.1 M Tris acetate buffer, pH 7.3, and 3 milliunits of each enzyme, containing protease inhibitors, was added to the tube. The reaction was allowed to proceed at 37°C for 3 h.
Streptomyces Hyaluronidase Digestion-IPM extract (100 g of total protein) was incubated in 50 mM sodium acetate buffer, pH 6.0, for 2 h at 37°C with Streptomyces hyaluronidase (2-5 turbidity reducing units). The reaction products were analyzed by staining with Gel Code stain after SDS-PAGE.
Western and Lectin Blotting-Equal protein concentrations were loaded on the gels prior to electrophoresis, transfer, and lectin blotting. The efficiency of electrotransfer to the membrane in the enzyme-treated preparation was assessed by comparing the SPACR staining intensity with Coomassie Blue in the gel before and after transfer. We found no significant difference in the transfer efficiency of the IPM before or after enzymatic treatment in any of these studies. SDS-PAGE-separated IPM samples were electroblotted onto Immobilon-P membranes and incubated in TBS, pH 7.5, for 30 min. TBS was replaced by the appropriate biotinylated lectin (20 g/ml) in 1% BSA-TBS and incubated for 3 h at room temperature. The membranes were washed with TBS (three times) and incubated with biotinylated horseradish peroxidase-avidin D complex, and the bands were visualized by the peroxidase reaction product. For Western blots, the membranes were incubated in 1:1000diluted primary anti-SPACR antiserum (5) in TBS overnight at 4°C after BSA blocking. Membranes were washed and incubated with alkaline phosphatase-conjugated secondary antibody (1:1000) for 1 h at room temperature. The membranes were washed, and the color reaction was developed using the substrates 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium.
Endoproteinase Lys-C, Trypsin, and Endoproteinase Glu-C Digestions-Protease digestions were carried out as described by Stone et al. (13) . Twenty micrograms of freeze-dried, purified SPACR was reduced and alkylated with iodoacetic acid. The enzyme (1:100 by weight) was added to SPACR in sodium bicarbonate buffer, pH 8.0, and incubated overnight at 37°C. The peptides were separated by standard reverse phase HPLC on a C-18 column using a gradient of acetonitrile in 0.1% trifluoroacetic acid. Sequencing of the isolated peptides was done in the Protein Core Facility of The Cleveland Clinic Foundation.
Cyanogen Bromide Cleavage-SPACR was N-deglycosylated as described (5), and 20 g was dissolved in 200 l of 70% trifluoroacetic acid. Cyanogen bromide (200 g) in acetonitrile was added to the tube, flushed with nitrogen, and incubated in the dark at an ambient temperature for 24 h. After diluting with 20 volumes of distilled water, the mixture was lyophilized. The peptides were separated by SDS-PAGE, transferred to polyvinylidene difluoride membranes, and subjected to sequencing by Edman degradation.
Mass Spectrometry-Affinity-purified SPACR was further separated on a 7.5% SDS-PAGE gel. The gel was stained with Coomassie Blue and the band was excised, and then the gel was destained and sent to the Harvard Microchemistry Laboratory (Harvard University, Cambridge, MA) for digestion with trypsin and separation by liquid chromatography/mass spectrometry. Four of the resultant peptides were sequenced by tandem mass spectrometry. All peptides were subjected to a BLAST search, which displayed 100% identities with peptides from the deduced sequence for IMPG1. The cDNA sequence of IMPG1 was submitted by M. H. Kuehn and G. S. Hageman to GenBank TM (accession number AF047492).
CPC Precipitation-To demonstrate HA binding to SPACR, we used a protocol previously described (14, 15) . Briefly, IPM extract in 0.1 M Tris acetate buffer, pH 7.3, containing 0.5 M NaCl and protease inhibitors was incubated at 37°C with 1.25% cetylpyridinium chloride (CPC) for 1 h. The extract was centrifuged (12,000 rpm) for 15 min at room temperature. The pellet was washed with 1% CPC in Tris acetate buffer and solubilized in Laemmli buffer (16), and both pellets and superna-tants were analyzed by SDS-PAGE followed by staining with Gel Code. BSA was included as a negative control.
3B3 Immunoblotting-Samples were immobilized on nitrocellulose membranes by the application of 25 l of IPM extract in TBS into wells of a Bio-Rad 96-well dot blot apparatus (17) . Proteins were adsorbed to the membrane for 1 h at room temperature before removing buffer and unbound molecules. The membrane was washed with Tris acetate buffer, pH 7.3, for 5 min and then incubated for 1 h in 5% nonfat milk powder in TBS. This was followed by a 4-h incubation with a 1:500 dilution of biotinylated 3B3 antibody at room temperature followed by a 1-h incubation with avidin-conjugated horseradish peroxidase solution. The bands were developed by peroxidase reaction with hydrogen peroxide and DAB.
Northern Blots-Total RNA from human tissues was either purchased from CLONTECH (Palo Alto, CA) or isolated from the human tissues using the RNAzol method (Cinna/Biotech Laboratory, Friendswood, TX). Macula and peripheral retina RNA was isolated from 5-mm punches of fresh monkey retina as described previously (18) . The RNA was separated by electrophoresis in 1% agarose 2.2 M formaldehyde gels. The gels were run in 20 mM MOPS, 5 mM sodium acetate, and 1 mM EDTA, pH 7.0 (19) .
Image Capture and Quantitation-Images of SDS-PAGE, immunoblots, and lectin blots were digitized at 300 dots per inch on a flat-bed Scanmaker III scanner, using Scan Wizard 3.0.7 software from Microtech Laboratories (Redondo Beach, CA). Band area and pixel density were measured using Kodak Digital Science software (Eastman Kodak Co.) on a Power Macintosh 7600/132 (Apple Computer, Cupertino, CA). Mean density and S.D. values were calculated from the pixel density in the bands of interest. The data were normalized to adjust for unequal background staining throughout the lane in the Coomassie Bluestained gels and lectin blots. At least three separate measurements were made for each treatment, and comparisons were made between treatments using a two-tailed Student's t test. All figures were assembled and labeled with PowerPoint 4.0 software (Microsoft Corp., Redmond, WA) and printed on a Codonics (Middleburg Heights, OH) NC 1600 dye substitution printer.
FIG. 1. Alignment of SPACR peptides with the predicted amino acid sequence of IMPG1 from GenBank TM (accession number AF047492), using single letter amino acid codes.
The deduced protein contains 771 amino acids, and the N-terminal signal peptide contains 70 residues (single underline). Seven potential Nlinked glycosylation sites (in boldface type) are present in two clusters on either side of a mucin-like domain containing numerous potential O-linked glycosylation sites (dotted underline from residue Gly 296 to Pro 552 ). An EGF-like domain (single underline from residue Asp 682 to Cys 729 ) containing six conserved cysteine residues (in boldface type) is present near the C terminus. An HA binding motif (double underline) is located at residues Lys 280 -Arg 292 . No consensus sites for GAG attachment are present in this deduced sequence. All SPACR peptides show 100% homology to IMPG1.
RESULTS AND DISCUSSION
Sequence Analysis-SPACR was purified on a WGA-Sepharose column after removal of all PNA-binding molecules to ensure a homogeneous population of WGA-binding protein (5) . The WGA-binding fraction was further separated by SDS-PAGE and transferred to polyvinylidene difluoride membranes, and the SPACR band was excised for sequence analysis. N-terminal sequencing was attempted on four separate occasions using increasing amounts of protein (from 2 to 20 pmol), which revealed that the majority of this protein is blocked (5) . However, using 20 pmol of protein, a low level signal (less than 1 pmol), corresponding to SAFFPTGVKV was obtained.
Seven peptides were obtained from solution digests of purified SPACR or in gel digests of SPACR separated by SDS-PAGE accounting for 9.1% of the protein sequence. Endoproteinase Glu-C digest yielded peptides EILDNTL and EFAVLEE. Cyanogen bromide cleavage yielded the peptide MQKIFKKL. Tandem mass spectrometric analysis, following trypsin digestion, yielded the peptides SAFFPTGVK, VC-QEAVWEAYR, AELADSQSPYYQELAGK, and QLEILNFR. The sequence of these seven peptides matched the predicted amino acid sequence of IMPG1 (AF047492) with 100% fidelity (Fig. 1) . These data indicate that the cDNA sequence submitted as IMPG1 is the sequence encoding SPACR.
Tissue Expression-The tissue distribution of SPACR expression was determined by Northern blot analysis using a variety of monkey and human tissues. To test for expression within the retina, 5-mm trephine isolates from different areas of the monkey retina were taken and the RNA isolated. Probes were designed from the cDNA sequence (see Fig. 2 for details).
SPACR mRNA was found in nearly equal amounts in macula and peripheral retina but was barely detectable in the pigmented epithelium/choroid (Fig. 2) . This low level of expression may be due to contamination from the neural retina, which is difficult to cleanly separate from the retinal pigment epithelium during tissue dissection. This is consistent with our data from human multitissue Northern blots, where the retina was the only tissue with detectable SPACR expression ( Fig. 3) . The mRNA is approximately 3.5 kb in length, consistent with the size of the cDNA sequence of IMPG1 (AF047492). The minor signal around 8 kb observed in the monkey retina lanes (Fig. 2 , lanes 1 and 3) may represent an alternative polyadenylation site in the mRNA. These results demonstrate the high level of specificity of this IPM protein to retina.
Features of the Deduced Sequence-The deduced amino acid sequence of IMPG1/SPACR is presented in Fig. 1 . Several interesting features are observed. Residues 1-70 represent a likely N-terminal signal peptide involved in the secretion of this IPM molecule. The natural N terminus of the mature protein was found to begin at position Ser 71 by N-terminal amino acid analysis of purified SPACR. The tryptic peptides derived from SPACR, which were analyzed by mass spectrometry, did not contain the peptides expected from the first 70 amino acid residues in the deduced sequence, confirming that this is a signal sequence. Thus, the mature SPACR protein contains 701 amino acid residues.
A large mucin-like domain, containing numerous potential O-linked glycosylation sites, lies in the central part of the protein (Gly 296 -Pro 552 ). Seven consensus sites for N-linked glycosylation are located in two clusters flanking either side of the mucin domain (at residues Asn 143 , Asn 191 , Asn 215 , Asn 592 , Asn 616 , Asn 630 , and Asn 648 , shown in boldface type in Fig. 1 ). This confirms and extends our previous direct glycoconjugate analysis of purified SPACR indicating that it contained both Nand O-linked glycoconjugates accounting for approximately 30% of the molecular mass (5) .
A linear HA binding motif of the RHAMM type (20, 21) is located at residues Lys 280 -Lys 288 . This motif conforms to the sequence pattern BX 7 B, where B represents lysine or arginine residues separated by seven amino acids, excluding aspartic or glutamic acid. This site is flanked by two proline residues (Pro 277 , Pro 289 ), which are known to be strong ␤-turn promoters, and may be required to present this motif in the appropriate conformation for HA binding.
An EGF-like motif is present on the C-terminal side of the mucin-like domain (Asp 687 -Cys 730 ). EGF-like domains are characteristic of a number of extracellular matrix proteins and are implicated in protein-protein interactions (22) (23) (24) (25) . The six conserved cysteine residues present in this domain are involved in intrachain disulfide bonding that is required for the structural stability of this motif (26) . Some EGF-like domains require calcium for their biological function (27) . Interestingly, the EGF-like domain in IMPG1/SPACR contains the critical asparagine (Asn 702 ), which has been implicated in calcium binding (27) . The potential for calcium binding by SPACR could point toward an important physiological role for this IPM protein in sequestering extracellular calcium released by photoreceptors in response to light (28, 29) .
Glycoprotein or Proteoglycan?-No documented consensus sites for GAG attachment are present in the deduced amino acid sequence of IMPG1/SPACR (Fig. 1) . Our biochemical analysis of SPACR indicates that this molecule is a glycoprotein (4, 5) . Based on electrophoretic mobility, the molecular mass of SPACR was defined as 147 kDa (4, 5) , which corresponds closely to the 150 kDa ascribed to IMPG1 after chondroitinase digestion (8 -10). If IMPG1 is the core protein of a chondroitin 6-sulfate proteoglycan, as claimed (8 -10), it should not enter a 7.5% SDS-PAGE unless the chondroitin sulfate chains are degraded. This, however, was not the result we observed when these comparisons were evaluated (Fig. 4A, lanes 1-3) . A prominent SPACR band is present in both chondroitinase-digested (Fig. 4A, lane 1) and undigested (Fig. 4A, lane 2) samples. The relative staining densities of the SPACR bands are not significantly different (see histogram in Fig. 4A ). The similarities in staining densities of the SPACR bands in these two groups indicate that additional protein with a molecular mass of 150 kDa is not released when the IPM is digested with chondroitinase.
In contrast, dramatic changes are observed in the higher molecular weight proteins. The high molecular weight components, which only minimally enter the gel in the undigested sample (Fig. 4A, lane 2) , are no longer observed after chondroitinase digestion (Fig. 4A, lane 1) . Instead, two new bands, one just above and the other below the 220-kDa marker, are now present (Fig. 4A, lane 1) . Since these bands are seen neither in the untreated sample (Fig. 4A, lane 2) nor in the enzyme control (Fig. 4A, lane 3) , they could only represent the core proteins of chondroitin or dermatan sulfate proteoglycans.
A polyclonal antibody to SPACR recognizes both native SPACR and SPACR treated with N-and/or O-glycosidases (5) . If the core protein of IMPG1 and SPACR represent the same gene product, the anti-SPACR antibody should recognize any IMPG1 molecules released after chondroitinase digestion, resulting in an increased intensity of immunostaining of the 150-kDa band. We used this antibody in Western blotting analysis (Fig. 4B, lanes 1-3) to determine whether increased im- munoreactivity could be detected in the 147-150-kDa band following chondroitinase digestion. Similar levels of SPACR immunoreactivity are observed in chondroitinase-digested (Fig. 4B, lane 1) , and undigested samples (Fig. 4B, lane 2) with no significant differences in the relative staining densities observed when the blots were quantitated (see histogram in Fig.  4B ). Additionally, in the undigested sample (Fig. 4B, lane 2) , no SPACR immunoreactivity is observed at the top of the lane where the high molecular weight proteoglycan bands are observed in the Coomassie Blue-stained gel (Fig. 4A, lane 2) . The two new bands present on either side of the 220-kDa marker, released after chondroitinase digestion (Fig. 4A, lane 1) , also fail to show SPACR immunoreactivity (Fig. 4B, lane 1) . These data indicate that no additional protein with epitopes recognized by the anti-SPACR antibody is released following chondroitinase digestion.
WGA was the principal lectin used for SPACR identification (3) (4) (5) . We used this lectin to determine whether additional WGA binding molecules are released following chondroitinase digestion. WGA blots of enzyme-treated and control IPM samples are presented in Fig. 5A, lanes 1 and 2. It should be noted that equal amounts of IPM protein (25 g of total protein) were loaded for all these comparisons. As previously reported (5) , SPACR is the most prominent WGA staining band in the IPM. The intensity in WGA staining of the SPACR band does not change with chondroitinase digestion (Fig. 5A, lane 1) from levels of staining in the undigested IPM sample (Fig. 5A, lane  2) . Although there is a general increase in background staining in the region between SPACR and the top of the lane after chondroitinase digestion (Fig. 5A, lane 1) , distinct increases in WGA staining of a band just above the 220-kDa marker and a broader, diffuse region below the 220-kDa marker are present. Lower levels of WGA staining occur in these regions of the undigested sample (Fig. 5A, lane 2) . The relative staining densities of SPACR and the two higher molecular weight bands were measured. Evident in the histogram presented in Fig. 5A , the higher molecular weight bands show a 2-3-fold increase following chondroitinase digestion, but the densities in the SPACR bands are not significantly different. The enzyme control (not shown) was free of WGA binding.
Although SPACR is predominantly a WGA-binding glycoprotein (5), a minor fraction also binds PNA. In the sample digested with chondroitinase (Fig. 5B, lane 1) , no significant increase in PNA staining of SPACR is observed over that present in the undigested IPM sample (Fig. 5B, lane 2) . This indicates that a PNA-positive molecule with a mass of 147-150 kDa is present before chondroitinase digestion and that no new PNA-positive molecules with this mass are liberated after chondroitinase digestion. However, higher molecular weight PNA binding bands are generated by this enzyme. New PNAstaining regions are present above and below the 220-kDa marker (Fig. 5B, lane 1) . The former is a distinct PNA band, whereas the latter is a broad smudge, composed of at least two closely spaced bands. These new PNA-positive bands are distinct and well separated from the 150-kDa SPACR band (Fig.  5B, lane 2) as evident in the histograms presented in Fig. 5B .
In an important series of papers, Hageman, Blanks, and Johnson (30 -32) first reported that the cone-associated IPM compartments contain glycoconjugates that bind PNA, a feature initially thought to be absent in the IPM surrounding rods. Chondroitin sulfate proteoglycans (31, 33) were also found to be uniquely localized to the IPM surrounding cones but not rods. 2) . The quantitative data presented in histograms show the relative staining densities of the distinct band above the 220-kDa marker (*), the band below the 220-kDa marker (**), and the SPACR band (at the level of the thick marker line). The histogram on the right presents the quantitative values of the WGA-staining densities in these bands. Two-to 3-fold increases in WGA staining density occur after chondroitinase digestion (hatched bar) over the density in the undigested samples (open bar) of the two higher molecular weight bands (p Ͻ 0.01 for comparisons between both bands), but no significant difference is evident between the SPACR band densities (p Ͼ0.1). B, PNA-lectin blot of IPM samples digested with chondroitinase (lane 1) or undigested (lane 2). The PNA blots shown and the density values were collected as described for A. Note the prominent new bands that occur above and below the 220-kDa marker. Quantitative data presented on the right show that SPACR staining with PNA is not significantly different before and after chondroitinase digestion (p Ͼ 0.1).
Further studies by Hageman and collaborators led to the description of two molecules from chondroitinase-digested IPM, which were referred to as IPM150 (now IMPG1) and IPM200. Although a complete biochemical characterization of IPM150 and IPM200 is not available in the peer-reviewed literature, some information is available in several abstracts (6 -9) and a review article (2) . A key feature is that neither IPM150 nor IPM200 will enter SDS-PAGE unless the IPM sample is digested with chondroitinase. In contrast to the results summarized above, we always observe a PNA-positive band in the 150-kDa region of both control and chondroitinase-treated samples of the human IPM. The new PNA binding band above 220 kDa (Fig. 5B, lane 1) may represent the previously described IPM200 (2, 6 -9) .
What is responsible for the PNA binding property of this minor fraction of SPACR? Carbohydrate analysis indicates that the dominant glycoconjugate determinant of SPACR is the O-linked carbohydrate NeuAc␣2-3Gal␤1-3GalNAc, which binds WGA and Maackia amurensis agglutinin-1 and -2 (5) . While most of the rod-associated matrix binds WGA and M. amurensis agglutinin-1 and -2 (4, 5) , PNA binding to the matrix surrounding a small population of rods in the human retina has also been documented (34) . PNA binding to SPACR can be efficiently achieved by removing the terminal sialic acid residues with neuraminidase, which exposes Gal␤1-3GalNAc residues that now readily bind PNA (4). Thus, it is likely that the PNA-binding fraction of SPACR represents asialo-SPACR or desialylated SPACR, which in the tissue may be responsible for the PNA binding to the matrix surrounding a small population of rods (34) .
The distribution of chondroitin 6-sulfate immunoreactivity in IPM samples digested with chondroitinase ABC was evaluated using 3B3, a monoclonal antibody, which is highly specific for chondroitin 6-sulfate ⌬-disaccharide (17) . Aggrecan (120 ng) from human knee cartilage, predigested with chondroitinase ABC, resulted in strong 3B3 binding (Fig. 6A ). When aggrecan was double-digested with chondroitinase ABC and then ACII to remove residual ⌬-disaccharides from the linkage oligosaccharide (35) , it no longer showed reactivity to 3B3, demonstrating the specificity of this antibody. Dot blots using increasing concentrations of total IPM protein, with and without chondroitinase ABC, displayed only faint 3B3 reactivity (Fig. 6B ). No differences were found between the digested and undigested IPM samples, and this staining intensity was only slightly greater than that observed using untreated aggrecan, which is known to have a 3B3 mimetope (17) . When similar concentrations of IPM were immunoblotted with the same antibody after separation on SDS-PAGE and transblotted, no SPACR reactivity with the 3B3 antibody was observed in samples either before or after chondroitinase digestion (Fig. 6C ). Altogether, these data convincingly demonstrate that SPACR, the gene product of IMPG1, is not a chondroitin 6-sulfated proteoglycan core protein. Additionally, none of the higher molecular weight bands that appear after chondroitinase digestion are recognized by this highly specific chondroitin 6-sulfate antibody, inconsistent with reports suggesting that these molecules are chondroitin 6-sulfated proteoglycan core proteins (2, 7) .
If the gene product of IMPG1 is the core protein of a proteoglycan, as has been stated in earlier reports (2, 6 -9) , the predicted amino acid sequence should contain at least one consensus sequence required for GAG attachment. GAGs are linked to serine residues in the core protein by way of a trisaccharide bridge, consisting of a xylose residue attached to serine, followed by two galactose residues (36) . Serine residues capable of functioning as xylosylation sites require the consensus sequence SGX, where X represents either glutamic acid or aspartic acid (37, 38) . The deduced amino acid sequence of IMPG1 does not contain an SGX consensus site. Although no other sequence for xylosylation has been documented in any mammalian proteoglycan core protein, two reports implicate the sequence EGSAD for GAG attachment in two avian proteoglycans (39, 40) . Such a sequence is not present in IMPG1. Mutagenesis studies, converting an SGD site to a TGD sequence, indicate that a threonine-substituted site can be xylosylated but with an efficiency of less than 10% that of SGD sites (41) . IMPG1 contains a TGE site (Thr 120 -Glu 122 ), but not a TGD site and should therefore be considered a proteoglycan only with supporting biochemical evidence. Our biochemical evidence indicates that there are no GAG chains on SPACR.
Hyaluronan Binding-CPC is a detergent that can, under nondissociative conditions, selectively precipitate GAGs along with any associated protein (42) . Recent studies demonstrate that HA is a normal constituent of the IPM (43). To explore the possible association of SPACR with HA, we used CPC to pre-FIG. 6. Dot blots of human IPM samples using 3B3 antibody to identify chondroitin 6-sulfate. A, the monoclonal antibody 3B3 reacts strongly with chondroitinase ABC-digested aggrecan (120 ng) but does not react with aggrecan digested with chondroitinase ACII. A lower staining intensity is sometimes observed (not visible here) with undigested aggrecan, which is known to act as a mimetope (12) . B, immunoreactivity of IPM samples with increasing concentrations of protein (5-50 g). Very faint reactivity was observed in both chondroitinase-digested and undigested IPM. Because only a faint impression of the sample was evident, for clarity each dot position has been faintly outlined. C, Western blot of IPM samples probed with 3B3. No immunoreactivity is seen at 150 kDa in the chondroitinase-digested (lane 1) or undigested (lane 2) sample. A weakly stained, nonspecific band is present in both samples at around 70 kDa. cipitate HA and other GAGs from human IPM extracts (Fig. 7,  lanes 1-8) . When an extract of IPM is treated with CPC, SPACR, along with some higher molecular weight bands, is observed in the pellet (lane 2). In our modified assay system, the IPM sample is pretreated with Streptomyces hyaluronidase (which specifically degrades HA). Following this digestion, no SPACR is evident in the CPC pellet (lane 4), but it is retained in the supernatant (lane 5). The ability of CPC to precipitate SPACR from the IPM sample and the failure to precipitate SPACR after hyaluronidase treatment suggest that SPACR forms associative interactions with HA. It should also be noted that the amount of SPACR that can be precipitated with CPC is proportional to the concentrations of SPACR and HA that are associated in the IPM sample used in the precipitation assay. The addition of exogenous HA did not significantly increase the amounts of SPACR precipitated (not shown). However, increasing the amounts of IPM resulted in higher levels of SPACR in the pellets (compare lane 6 with lane 7). These results suggest that SPACR and HA co-exist as a saturated complex in IPM extracts under associative buffer conditions (without chaotropic agents, detergents, or reducing agents) and readily form the complex that co-precipitates in the presence of CPC. As a control for nonspecific trapping of protein in the CPC-HA precipitate, BSA mixed with 0.5% HA (Healon), was also prepared (lane 8). No precipitation of BSA with CPC was observed, indicating that SPACR co-precipitates with CPC because of specific associations with HA.
These CPC precipitation results suggest that the RHAMMtype HA binding motif present in SPACR at Lys 280 -Arg 292 is functionally active, although mutagenesis studies of this motif will be required to verify this role. Since digestion of HA with Streptomyces hyaluronidase results in the loss of the ability of CPC to precipitate SPACR, this finding suggests that SPACR binds mainly to HA and not to other IPM GAGs. Mutagenesis studies of the putative HA binding motif will be required to establish this as the site of HA binding. The complex of SPACR and HA could have an important role in the organization of the matrix and its adhesion to the cells that border the IPM via protein-carbohydrate and/or carbohydrate-carbohydrate interactions.
The IMPG1/SPACR gene is located on chromosome 6q (10) . A number of macular dystrophies have been linked to this locus in humans (44 -46) . Although no specific mutations have yet been identified (44) , the gene for this abundant IPM protein is a potential candidate locus for inherited retinal disorders.
In summary, the peptide sequence information we obtained from the human glycoprotein SPACR is 100% homologous to the predicted amino acid sequence of IMPG1. The predicted polypeptide for IMPG1/SPACR has no established consensus site for GAG attachment, and the protein is not a product of chondroitinase digestion and displays no immunoreactivity to an anti-proteoglycan chondroitin 6-sulfate antibody. We conclude that the cDNA sequence of IMPG1 is not the core protein for a chondroitin 6-sulfate proteoglycan but instead is the gene for the IPM glycoprotein we describe as SPACR (5) . SPACR has a functional binding domain for HA, suggesting that interactions between SPACR and HA may serve to organize the basic macromolecular scaffold, which comprises the insoluble IPM.
